Clinicohemodynamic efficacy of a selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease


Cite item

Full Text

Abstract

Aim. To assess the effect of a long-term (6 months) treatment with selective beta-blocker bisoprolol, cytoprotector trimetazidine and their combination on the clinical course, left ventricular morphofunctional parameters and quality of life of patients with ischemic heart disease (IHD) with chronic heart failure(CHF) functional class III-IV.
Material and methods. A total of 71 IHD patients with CHF (FC III-IV) entered the study. In group 1 basic therapy was combined with bisoprolol, in group 2 - with trimetazidine, in group 3 - with bisoprolol + trimetazidine. The initial dose of bisoprolol was 1.25 mg with subsequent dose titration to individually tolerated. Trimetazidine was given in a dose 20 mg 3 times a day. Clinical tests and echocardiography parameters were assessed monthly.
Results. CHF functional class decreased in all the groups. End diastolic and systolic volumes of the left ventricle reduced, while ejection fraction increased. The best treatment results were achieved in combination of bisoprolol with trimetazidine (LV EF increased by 42.6%, while Ve/Va decreased by 59%).
Conclusion. Clinicohemodynamic benefit obtained after long-term administration of bisoprolol, trimetazidine and their combination in IHD patients with CHF (Fc III-IV) justifies inclusion of these drugs as monotherapy and combined treatment of CHF in IHD.

References

  1. Ghali J. К., Kay R., Shelton B. et al. Contemporary aetiologies of left ventricular dysfunction and/or heart failure and their influence on prognosis. Circulation 1992; 86 (suppl.): 2380.
  2. Come M. R., Mosterd A., Wood D. A. et al. The epidemiology of heart failure. Eur. Heart J. 1997; 18: 208-225.
  3. Sayen J. J., Sheldon W. F., Peirce G., Kuo P. T. Polarographic oxygen, the epicardial electrocardiogram and muscle contraction in experimental acute regional ischemia of the left ventricle. Circ. Res. 1958; 6: 779-798.
  4. Tatooles С. J., Randall W. С. Local ventricular building after acute coronary occlusion. Am. J. Physiol. 1961; 201: 451-456.
  5. Olivier V., Opie L. Effects of glucose and fatty acid on myocardial ischemia and arrhythmias. Lancet 1994; 343: 155-158.
  6. Lopaschuk G. D., Belke D. D., Gamble J. et al. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim. Biophys. Acta 1994; 1213: 263-276.
  7. King L. M., Opie L. H. Glucose and glycogen utilization in myocardial ischemia - change in metabolism and consequences for the myocyte. Mol. Cell. Biochem. 1998; 180: 3-26.
  8. Dennis S. C., Gevers W., Opie L. H. Protons in ischemia: where do they come from, where do they got to? J. Mol. Cell. Cardiol. 1991; 23: 1077-1086.
  9. Hansford R. G., Cohen L. Relative importance of piruvate dehydrogenase interconversion and feedback inhibition in the effect of fatty acids on piruvate oxidation by rat heart mitochondria. Arch. Biochem. Biophys. 1978; 191: 65-81.
  10. Renaud J. F. Internal pH, Na, and Ca regulation by trimetazidine during cardiac cell acidosis. Cardiovasc. Drug Ther. 1988; 1: 677-686.
  11. Honore E., Adamantidis M. M., Challice C. E. et al. Cardioprotection by calcium antagonists, pyridoxilate and trimetazidine. IRSC Med. Sci. 1986; 14: 938-939.
  12. Roulet M. J., Gamier D. The anti-anginal drug, trimetazidine, potentiates the tension on hypoxic ductus arteriosus. Inserm 1984; 124:481-488.
  13. Maridonneau-Parini I., Harpey С. Effects of trimetazidine ion membrane damage induced by oxygen free radicals in human red cells. Br. J. Clin. Pharmacol. 1985; 20: 148-151.
  14. Passeron J. Clinical efficacy of trimetazidine in stable angina pectoris. Presse Med. 1986; 15: 1775-1778.
  15. Dalla-Volta S., Maraglino G., Della-Valentina P. et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc. Drugs Ther. 1990; 4: 853-860.
  16. Терещенко С. Н., Акимова О. С., Коровина Е. А., Моисеев В. С. Клинико-гемодинамическая эффективность триметазидина в комплексной терапии ранней постинфарктной стенокардии. Клин, фармакол. и тер. 1996; 3: 17-20.
  17. Колычева С. В., Ходарева Е. Н., Жарова Е. А. Клинико-инструментальная оценка эффективности предуктала у больных ИБС. Практикующий врач 1999; 15.
  18. Жарова Е. А., Лепахин В. К., Фитилев С. Б. и др. Триметазидин в комбинированной терапии стенокардии напряжения. Сердце 2002; I (4): 204-207.
  19. Kantor P., Lucien A., Kozak R., Lopaschuk G. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial Long-Chain 3-Ketoacyl-Coenzym A Thiolase. Circ. Res. 2000; 86: 580-588.
  20. Brottier L., Barat J. L., Combe C. et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur. Heart J. 1990; 11: 207-212.
  21. Бузиашвили Ю. И., Маколкин В, И., Осадчий К. К. и др. Влияние триметазидина на обратимую дисфункцию миокарда при ишемической болезни сердца. Кардиология 1999; 6: 33-38.
  22. Терещенко С. Н., Акимова О. С., Демидова И. В. и др. Цитопротектор триметазидин в комплексной терапии тяжелой постинфарктной хронической сердечной недостаточности. Кардиология 1999; 9: 48-52.
  23. Недошивин А. О., Кутузова А. Э., Нестерова И. В. и др. Триметазидин в коррекции хронической сердечной недостаточности у больных ишемической болезнью сердца. Кардиология 2002; 3: 12-15.
  24. Bristow M. R. Mechanism of action of beta-blocking agents in heart failure. Am. J. Cardiol. 1997; 80: 26L-40L.
  25. Bristow M. R., Gilbert E. M. Improvement of cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur. Heart J. 1995; 16 (suppl. F): 20-31.
  26. CI BIS Investigators and Committees. A randomized trial (5blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.
  27. Eichhorn E. J., Heesch C. M., Barnett J. H. et al. Effects of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol. 1994; 24: 1310-1320.
  28. Packer M., Bristow M. R., Cohn J. N. et al. Effects of carvediloi on morbidity and mortality in chronic heart failure. N. Engl. J. Med. 1996; 334: 1349-1355.
  29. Waagstein F., Bristow M. R., Swedberg K. et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
  30. Агеев Ф. Т. Влияние современных медикаментозных средств на течение заболевания, качество жизни и прогноз больных с различными стадиями хронической сердечной недостаточности: Дис. ... д-ра мед. наук; 1997.
  31. Агеев Ф. Т., Мареев В. Ю., Лопатин Ю. М., Беленков Ю. Н. Роль различных клинических, гемодинамических и нейрогуморальных факторов в определении тяжести хронической сердечной недостаточности. Кардиология 1995; 11: 4-11.
  32. Ахмедярова Н. К. Неинвазивная оценка миокардиального резерва и состояния диастолической функции у больных ИБС с обратимой дисфункцией миокарда по данным стресс-эхокардиографии с добутамином: Дис. ... канд. мед. наук; 2000.
  33. Lu С., Dabrowski P., Fragasso G., Chierchia S. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am. J. Cardiol. 1998; 82: 898- 901.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies